RAD51C and breast cancer: The National Comprehensive Cancer Network (NCCN) guidelines report on mutations in BRIP1 and RAD51C as being a cause for potential increase in breast cancer risk (specifically for triple negative breast cancers), but there is insufficient evidence for risk management [33].